Cardiovascular

Anticoagulation reversal for warfarin and direct oral anticoagulants

Clinical Overview and When to Suspect Major Anticoagulant-Related Bleeding

— Any patient on AC with new neurologic deficit, severe headache, syncope, abdominal/flank pain, melena, hematuria, or hypotension

— Trauma patients on AC, even minor head strikes (CT head mandatory in anyone on AC with head trauma)

— Unexplained anemia or hemodynamic instability in elderly polypharmacy patients

— Major bleeding: intracranial hemorrhage (ICH), retroperitoneal, intraocular, pericardial, intraspinal, compartment syndrome, Hgb drop ≥2 g/dL, transfusion ≥2 U pRBC, or hemodynamic instability

— Life-threatening: above + shock, critical organ involvement, or need for emergent surgery

— Non-major: epistaxis, minor cuts, bruising — usually managed with hold + local measures

— Which anticoagulant, last dose timing, indication (mechanical valve vs AFib vs VTE — affects re-initiation)

— Renal/hepatic function (alters DOAC clearance dramatically)

— Concurrent antiplatelets, NSAIDs, supratherapeutic INR triggers

Step 3 management: In a CCS case, the first 3 orders for any suspected major AC bleed should be 2 large-bore IVs, type & crossmatch, CBC/coags/renal panel — then move to imaging and specific reversal. Document time of last anticoagulant dose on every chart; this single data point determines whether reversal is even pharmacologically useful for DOACs.

Scope of problem: Anticoagulant-associated bleeding is among the most common drug-related ED presentations. Warfarin and DOACs (dabigatran, apixaban, rivaroxaban, edoxaban) require distinct reversal strategies — the wrong agent wastes time and costs lives.

When to suspect anticoagulant bleeding:

Classify bleed severity immediately — drives reversal decisions:

Key first-line questions:

Reversal hierarchy: mechanical hemostasis + supportive care first, then targeted reversal agent. Reversal does not replace surgical/endoscopic source control.

Presentation Patterns and Key History

— Sudden headache, focal deficit, altered mental status, seizure, or coma

— Warfarin ICH mortality ~50%; DOAC ICH mortality lower but still 25–35%

— Spontaneous ICH risk: warfarin > dabigatran ≈ apixaban; apixaban has the lowest ICH rate among DOACs

— Hematemesis, melena, hematochezia, fatigue, orthostasis

— Dabigatran and rivaroxaban have higher GI bleed rates than warfarin or apixaban

— Upper GI source more common in elderly; lower GI source increases with age (diverticular, AVMs)

— Flank pain + drop in Hgb without obvious source → suspect retroperitoneal hematoma (CT abdomen without contrast initially, then with if stable)

— Spontaneous rectus sheath or iliopsoas hematomas in elderly women on warfarin after coughing

— Drug name, dose, dose interval, time of last dose (critical for DOACs with short half-lives)

— Indication: mechanical valve = high thrombotic risk if reversed; AFib with low CHA₂DS₂-VASc = lower risk

— Renal function (CrCl) and hepatic function — DOAC accumulation occurs with AKI

— Drug interactions: amiodarone, azoles, macrolides ↑ warfarin INR; P-gp/CYP3A4 inhibitors ↑ DOAC levels

— Recent procedures, falls, GI symptoms preceding bleed

— Cauda equina from spinal epidural hematoma — back pain + saddle anesthesia + urinary retention → emergent MRI

— Pericardial tamponade — Beck triad in patient with recent ablation or pacemaker on AC

Board pearl: A patient on dabigatran with vomiting and confusion 4 hours after the last dose — assume drug is still systemically active; idarucizumab is appropriate. The same patient 36 hours out with normal renal function likely has subtherapeutic drug levels and may not need reversal.

Intracranial hemorrhage (highest-stakes presentation):

GI bleeding (most common AC-related major bleed):

Genitourinary, retroperitoneal, soft-tissue:

History essentials (the "AC bleed checklist"):

Atypical presentations:

Physical Exam Findings and Hemodynamic Assessment

— Airway: GCS ≤8, expanding neck hematoma (post-carotid procedure), or oropharyngeal bleeding → intubate early

— Breathing: hemothorax, pulmonary hemorrhage with hemoptysis

— Circulation: HR, BP, capillary refill, mottling — shock index (HR/SBP) >1.0 predicts massive transfusion need

— Disability: GCS, pupils, focal deficits, NIHSS in suspected ICH

— Exposure: full skin survey for petechiae, ecchymoses, occult bleeding sites

— Compensated: tachycardia with preserved BP — elderly on beta-blockers may not mount tachycardia; do not be falsely reassured

— Decompensated: hypotension, altered mental status, oliguria — initiate massive transfusion protocol (MTP) alongside reversal

— Permissive hypotension generally NOT applied to AC-associated ICH; target SBP <140 mmHg in spontaneous ICH per AHA

— Neuro: pupil asymmetry, posturing, Cushing triad (HTN, bradycardia, irregular respirations) → impending herniation

— Abdomen: distension, rigidity, Cullen/Grey-Turner signs (retroperitoneal bleed)

— Rectal: gross blood, melena, mass

— Skin: bruising pattern can suggest elder abuse vs. coagulopathic bleeding; document carefully

— FAST exam for free fluid in trauma or unexplained hypotension

— Cardiac for pericardial effusion/tamponade

— IVC collapsibility for volume status

Key distinction: A warfarin patient with isolated mucocutaneous bleeding and INR 6 without organ-threatening hemorrhage requires only oral vitamin K and hold — NOT 4F-PCC. Reserve PCC for life-threatening or major bleeding. Overtreatment causes thrombosis, especially with mechanical valves or recent VTE.

Step 3 management: Order q15-minute vitals, continuous telemetry, NPO, and serial neuro checks q1h in any AC bleed with hemodynamic instability or suspected ICH while reversal is being prepared.

Primary survey (ABCDE) drives early reversal urgency:

Hemodynamic phenotypes:

Focused exam by suspected site:

Bedside POCUS:

Diagnostic Workup — Initial Labs, Imaging, and Coagulation Testing

— CBC with platelets, BMP (creatinine for DOAC clearance), LFTs, type & screen/crossmatch

— PT/INR, aPTT, fibrinogen — fibrinogen <150 mg/dL in trauma predicts massive bleeding

— Lactate, VBG for shock assessment

— Beta-hCG in reproductive-age women (affects imaging and drug choices)

— Warfarin: INR directly guides reversal. INR >1.5 confirms anticoagulant effect; target post-reversal INR <1.5 (for ICH, some advocate <1.3)

— Dabigatran: prolongs aPTT and thrombin time (TT); a normal TT essentially excludes clinically significant dabigatran effect. Dilute TT or ecarin clotting time quantifies level if available

— Factor Xa inhibitors (apixaban, rivaroxaban, edoxaban): PT/aPTT are unreliable — may be normal despite therapeutic levels. Anti-Xa level calibrated to the specific drug is the gold standard; an undetectable anti-Xa rules out significant drug effect

— Standard anti-Xa (heparin-calibrated) can be used qualitatively if drug-specific assay unavailable

— Non-contrast head CT for any AC patient with head trauma, headache, or neuro symptoms — within 30 minutes of arrival

— CT angiography of head/neck if dissection or vascular lesion suspected

— CT abdomen/pelvis with IV contrast for suspected intra-abdominal/retroperitoneal bleeding (non-contrast if AKI)

— Endoscopy (EGD/colonoscopy) for GI bleeding after stabilization

Board pearl: A normal PT/aPTT does NOT exclude rivaroxaban or apixaban effect. If a patient on apixaban presents with ICH and the institution lacks anti-Xa testing, treat empirically based on time since last dose — if within 3–5 half-lives (~15–18 hours for apixaban with normal renal function), assume drug is active and reverse if bleeding is major.

Mandatory initial labs for any suspected AC bleed:

Coagulation test interpretation by agent:

Imaging by site:

ECG: baseline rhythm, signs of demand ischemia from anemia, electrolyte derangements from massive transfusion

Diagnostic Workup — Advanced and Confirmatory Studies

— Dilute thrombin time (dTT) or ecarin clotting time (ECT) — quantitative for dabigatran

— Drug-calibrated anti-Xa — quantitative for apixaban, rivaroxaban, edoxaban; reported in ng/mL

— Levels >30 ng/mL generally considered clinically significant; <30 ng/mL likely doesn't require reversal

— Turnaround time is often a limiting factor — most EDs treat empirically

— Viscoelastic testing helpful in trauma and massive bleeding to guide product use

— Limitations: insensitive to DOACs at therapeutic levels; better for identifying fibrinogen deficit, platelet dysfunction, and hyperfibrinolysis

— Repeat head CT at 6 hours post-ICH or with neurologic change to assess hematoma expansion (a key driver of mortality)

— Stable hematoma + reversed coagulopathy supports continued medical management

— EGD within 24 hours for upper GI bleed

— CT angiography for brisk lower GI bleed (>0.3 mL/min) → IR embolization

— Tagged RBC scan for slow intermittent bleeding

— TTE/TEE for endocarditis if AFib patient with embolic stroke + ICH conversion

— MRI spine for back pain + neurologic findings (epidural hematoma)

— Vascular imaging for mechanical valve assessment before considering AC resumption

Step 3 management: For any anticoagulated patient with ICH, order repeat non-contrast head CT at 6 hours and serial neuro checks q1h x 24h, then q2h. Hematoma expansion peaks in the first 6 hours — this window drives the urgency of complete reversal within 60 minutes of diagnosis.

Key distinction: Anti-Xa assay calibrated for heparin can detect Xa inhibitor presence qualitatively but cannot quantify drug level accurately — use as a screen, not for dosing decisions about reversal agents.

Drug-specific quantitative assays (if available):

Thromboelastography (TEG) / ROTEM:

Repeat imaging:

Source localization for GI bleeding:

Additional workup based on context:

Risk Stratification and Reversal Decision Logic

— 1. Is the bleeding major or life-threatening? (ISTH criteria)

— 2. Is the anticoagulant pharmacologically active? (time since last dose, renal function, lab evidence)

— 3. What is the thrombotic risk of reversal? (mechanical valve, recent stroke, LV thrombus)

— Life-threatening bleeding (ICH, retroperitoneal, ocular, airway) — always reverse

— Major bleeding with hemodynamic instability or failed local control — reverse

— Emergent surgery within 6–24 hours that cannot be delayed — reverse

— Supratherapeutic INR without bleeding — generally do NOT use PCC; use vitamin K ± dose hold

— Minor bleeding controllable with local measures

— Asymptomatic elevated INR

— Bleeding >3–5 half-lives after last DOAC dose (drug already cleared)

— Active thrombosis (acute PE, LV thrombus) — risk/benefit shifts; consult hematology

— ICH score and GCS stratify ICH mortality

— HAS-BLED is for chronic bleeding risk assessment, not acute decisions

— Shock index, lactate, base deficit guide MTP activation

— Mechanical mitral valve, recent (<3 months) VTE, LV thrombus, recent stroke — high thrombotic risk; restart AC as soon as hemostasis achieved

— AFib with CHA₂DS₂-VASc 2–4 — moderate risk; delay restart 1–2 weeks for ICH, 3–7 days for GI bleed

— AFib CHA₂DS₂-VASc ≥5 — high risk despite ICH; multidisciplinary decision

CCS pearl: In a CCS case, document the indication for AC and most recent dose timing in the first 5 minutes — these data points unlock the entire reversal pathway and demonstrate Step 3-level systems thinking. Then activate the massive transfusion protocol if hemodynamically unstable in parallel with specific reversal.

Core decision framework — three questions:

When to reverse:

When NOT to reverse:

Severity scoring:

Thrombotic risk anchors:

Pharmacotherapy — Specific Reversal Agents by Drug

— 4-factor PCC (Kcentra): dose 25–50 U/kg IV based on INR (25 U/kg if INR 2–4, 35 if 4–6, 50 if >6); max 5000 U. Onset within minutes. Preferred over FFP for major bleeding/ICH

— Vitamin K 10 mg IV over 30 minutes — co-administer with PCC; sustains reversal beyond PCC half-life (~6 hours). Oral vitamin K for non-urgent INR reversal

— FFP (10–15 mL/kg) — second-line; slower, volume-intensive, risk of TRALI/TACO. Use only if PCC unavailable

— Recheck INR 30 minutes after PCC; target <1.5 (or <1.3 for ICH)

— Idarucizumab (Praxbind): 5 g IV (two 2.5 g vials given consecutively). Monoclonal Fab fragment binds dabigatran with 350× the affinity of thrombin. Onset within minutes, complete reversal

— Hemodialysis is an alternative if idarucizumab unavailable (dabigatran is 80% renally cleared, low protein binding)

— Activated charcoal if last dose within 2–4 hours

— Andexanet alfa (Andexxa): low-dose (400 mg bolus + 480 mg infusion) or high-dose (800 mg bolus + 960 mg infusion) based on agent, dose, and time since last dose

— Approved for apixaban/rivaroxaban; off-label for edoxaban/enoxaparin

— 4F-PCC 50 U/kg is the pragmatic alternative when andexanet is unavailable, contraindicated, or cost-prohibitive — supported by guidelines despite indirect evidence

— Andexanet temporarily renders heparin ineffective — problematic if patient needs cardiopulmonary bypass

— Tranexamic acid 1 g IV for trauma within 3 hours, mucosal bleeding, intracranial hemorrhage (CRASH-3 supports for ICH within 3h)

— Platelet transfusion only if platelets <50K (or <100K for ICH) or on antiplatelet with major bleed

— Activated charcoal if oral DOAC ingestion within 2 hours

Board pearl: Idarucizumab is dabigatran-specific — do not give it for Xa inhibitor bleeding. Conversely, andexanet does not reverse dabigatran. Mixing them up is a classic distractor on exams.

Warfarin reversal:

Dabigatran reversal:

Factor Xa inhibitor reversal (apixaban, rivaroxaban):

Adjuncts (all bleeds):

Procedures, Massive Transfusion, and Source Control

— Activate for shock + ongoing bleeding, anticipated >10 U pRBC in 24h, or ABC score ≥2

— 1:1:1 ratio of pRBC:FFP:platelets

— Goals: Hgb >7 (>8 if cardiac disease), platelets >50K (>100K for CNS bleed), fibrinogen >150 mg/dL, INR <1.5, ionized Ca >1.1, temp >36°C, pH >7.2

— Cryoprecipitate if fibrinogen <150 mg/dL (10 units raises fibrinogen ~70 mg/dL)

— Avoid hypothermia, acidosis, hypocalcemia (the lethal triad)

— Neurosurgery consult immediately for hematoma >30 mL, cerebellar bleed, hydrocephalus, or GCS deterioration

— SBP target <140 mmHg (avoid <110); IV nicardipine or labetalol

— Elevate head of bed 30°, normothermia, normoglycemia, seizure prophylaxis only if cortical or active seizure

— Hyperosmolar therapy (mannitol, hypertonic saline) for elevated ICP/herniation signs

— EGD with hemostasis (clips, thermal, epinephrine, banding for varices) — generally within 24h

— Colonoscopy for lower GI bleed after prep

— IR embolization for brisk bleeding not amenable to endoscopy

— Surgery for refractory bleeding or specific lesions

— IR embolization for retroperitoneal, splenic, hepatic, renal bleeding

— Surgical decompression for compartment syndrome, expanding hematoma compressing critical structures

— Pericardiocentesis for tamponade

— Dabigatran: hemodialyzable (effective adjunct when idarucizumab unavailable)

— Apixaban, rivaroxaban: highly protein-bound, NOT dialyzable

CCS pearl: In a CCS case of variceal bleed in an anticoagulated cirrhotic, the order set is IV access ×2, type & cross, octreotide, ceftriaxone, PPI, GI consult for emergent EGD, reverse coagulopathy with PCC + vitamin K, and admit to ICU. Forgetting prophylactic antibiotics (ceftriaxone reduces mortality in variceal bleeders) is a common omission.

Massive transfusion protocol (MTP):

Intracranial hemorrhage management:

GI bleeding source control:

Other procedural source control:

Dialysis considerations:

Special Populations — Elderly and Renal/Hepatic Impairment

— Highest bleeding risk group; also highest thrombotic risk if AC withheld

— Apixaban dose reduction to 2.5 mg BID if ≥2 of: age ≥80, weight ≤60 kg, Cr ≥1.5

— Falls assessment is part of reversal workup — recurrent falls + ICH may warrant LAA occlusion (Watchman) instead of resuming AC

— Polypharmacy review: PPI, statin, amiodarone interactions amplify warfarin effect

— Lower threshold for imaging — minor head trauma in elderly on AC mandates CT

— Dabigatran is 80% renally cleared; CrCl <30 mL/min → drug accumulates dangerously; avoid altogether at CrCl <15

— Rivaroxaban, edoxaban, apixaban are partially renally cleared (~25–50%); dose adjustments per CrCl

— In AKI superimposed on CKD, DOAC levels can be markedly elevated despite "appropriate" last dose timing — lower threshold to reverse

— For dabigatran patients in AKI: hemodialysis is both reversal and renal support

— Avoid andexanet dose adjustments based on renal function — pharmacokinetics not significantly affected

— Warfarin effect amplified in cirrhosis due to reduced clotting factor synthesis; baseline INR may be elevated without "anticoagulant effect"

— Rivaroxaban contraindicated in Child-Pugh B/C

— Apixaban: caution in Child-Pugh B, avoid in C

— Cirrhotic bleeding requires multidisciplinary approach — PCC may add thrombotic risk (portal vein thrombosis)

— Time-limited trials of reversal/aggressive care; engage goals of care discussions early

— Discuss code status before intubation when possible

Step 3 management: In an 82-year-old on dabigatran with CrCl 22 mL/min and major GI bleed, order idarucizumab 5 g IV, activated charcoal if <2h ingestion, hold AC, and consult nephrology for emergent hemodialysis if idarucizumab is unavailable. Document family/POA discussions about AC resumption — long-term decision is rarely made in the ED.

Elderly (>75) considerations:

Renal impairment:

Hepatic impairment:

Frailty considerations:

Special Populations — Pregnancy, Pediatrics, and Mechanical Valves

— Warfarin is teratogenic (warfarin embryopathy: nasal hypoplasia, stippled epiphyses, CNS abnormalities), especially weeks 6–12; crosses placenta

— DOACs are not recommended in pregnancy — insufficient data, likely placental transfer

— LMWH is the standard anticoagulant in pregnancy; reverse with protamine (incomplete reversal, ~60%)

— If pregnant patient presents on warfarin (e.g., mechanical valve) with major bleeding: PCC + vitamin K; coordinate with OB for fetal monitoring

— Postpartum hemorrhage in anticoagulated patient: TXA 1g IV, uterotonics, PCC for warfarin, idarucizumab/andexanet/PCC for DOACs based on agent

— DOACs FDA-approved for pediatric VTE (dabigatran, rivaroxaban) with weight-based dosing

— Reversal data limited; extrapolate adult protocols with weight-adjusted dosing

— Vitamin K dose 0.5–5 mg in pediatric warfarin overdose

— Only warfarin is approved (DOACs contraindicated — RE-ALIGN trial showed increased thrombosis with dabigatran)

— Reversal in mechanical valve patient is high-stakes: bridge with UFH ASAP after hemostasis (typically 24–72h post-ICH, sooner for non-CNS bleeds)

— Aortic mechanical valve: lower thrombotic risk; mitral or multiple valves: highest risk

— Consult cardiology and cardiac surgery before final restart plan

— IVC filter consideration if AC must be held >2 weeks; retrievable filter with documented removal plan

— Filter is bridge, not destination — high complication rate if left permanently

Board pearl: A pregnant woman with a mechanical mitral valve on warfarin with major bleeding requires 4F-PCC + vitamin K + immediate OB and cardiology consultation. Restart heparin (UFH or LMWH) within 24–72 hours; switching back to warfarin depends on trimester and delivery planning. Never give DOAC to a mechanical valve patient.

Pregnancy:

Pediatrics:

Mechanical heart valves:

Recent VTE (<3 months):

Complications and Adverse Outcomes

— Hematoma expansion in ICH: peaks first 6 hours; predicts mortality and disability

— Compartment syndrome from intramuscular bleed: pain out of proportion, paresthesias, pallor — emergent fasciotomy

— Acute kidney injury from hypoperfusion + heme pigment + contrast nephropathy

— Bowel ischemia from prolonged hypotension

— Cardiac demand ischemia from anemia → troponin elevation

— Thrombotic events post-reversal: 4F-PCC ~5%, andexanet 10–15%, idarucizumab ~5%

– Stroke, MI, DVT/PE, mechanical valve thrombosis

– Risk highest in patients with strong underlying thrombotic indication

— Andexanet specifically: heparin resistance during subsequent UFH use (significant for CV surgery patients) and possible rebound in anti-Xa activity after infusion ends

— Idarucizumab: rare anaphylaxis (hereditary fructose intolerance — contains sorbitol), rebound dabigatran activity if redistribution from tissues

— 4F-PCC: thrombosis, DIC (rare), hypersensitivity, heparin-induced thrombocytopenia (contains small amount of heparin)

— FFP: TRALI, TACO, allergic transfusion reaction

— Vitamin K IV: rare anaphylaxis; give slowly (over 30 min)

— Hypocalcemia (citrate), hyperkalemia (lysed cells), coagulopathy, hypothermia, acidosis

— Monitor ionized calcium, replace empirically with massive transfusion

— Persistent bleeding despite reversal → reassess source control, mechanical hemostasis, additional product, or repeat dosing

— Recheck coagulation parameters 30 minutes post-administration

Key distinction: Thrombosis after reversal is not malpractice — it is an expected risk in patients on AC for thrombotic indications. Document the indication, severity of bleed, and shared decision-making. The alternative (death from uncontrolled hemorrhage) is worse. Mitigate by restarting AC as soon as hemostasis allows.

Bleeding-related complications:

Reversal-agent complications:

Massive transfusion complications:

Failure to reverse:

When to Escalate — ICU, Consults, and Disposition

— All ICH requiring reversal

— Hemodynamic instability requiring vasopressors or massive transfusion

— Active major bleeding requiring frequent reassessment

— Post-procedural surveillance after embolization or surgery

— Mechanical ventilation or airway concern

— Stabilized GI bleed with controlled source post-endoscopy

— Reversed coagulopathy with stable Hgb and no further bleeding

— Requires q4h vital signs and serial labs

— Hematology: complex reversal, refractory bleeding, restart timing, prothrombotic states

— Neurosurgery: all ICH cases, even if non-operative

— GI: all upper or lower GI bleeds

— Cardiology/CT surgery: mechanical valves, recent PCI

— Trauma surgery: blunt/penetrating trauma with AC

— Interventional radiology: embolization candidates

— Pharmacy: dosing, drug interactions, second-line agents

— Lack of neurosurgical coverage + ICH → transfer after stabilization and reversal initiation (do not delay reversal for transfer)

— Lack of specific reversal agent (e.g., andexanet) → consider 4F-PCC as bridge and transfer for definitive care

— Use closed-loop communication and document time of reversal agent administration

— Massive ICH with poor prognosis: discuss with family early; palliative care consult

— Pre-existing advance directive must be reviewed before aggressive intervention

CCS pearl: In a CCS case, after activating reversal, the next moves are consult neurosurgery (if ICH), admit to ICU, place arterial line for BP monitoring, foley catheter for I/O monitoring, and order serial CBC q4h, INR q6h until <1.5 sustained. Don't forget to discontinue all antiplatelet agents and document why (or why not).

ICU admission criteria:

Step-down/telemetry:

Multidisciplinary consults — call early:

Transfer considerations:

Goals of care:

Key Differentials — Other Coagulopathies and Same-Category Mimics

— Heparin (UFH): reverse with protamine 1 mg per 100 U heparin given in past hour; max 50 mg; slow IV push (risk of hypotension)

— LMWH (enoxaparin): partial reversal with protamine — 1 mg per 1 mg enoxaparin if <8h, 0.5 mg per 1 mg if 8–12h; only ~60% effective due to anti-Xa activity

— Fondaparinux: no specific antidote; andexanet alfa off-label or recombinant factor VIIa as salvage

— Argatroban, bivalirudin (direct thrombin inhibitors): no antidote; supportive care, short half-lives, consider dialysis for argatroban

— Thrombolytics (tPA): cryoprecipitate, FFP, TXA, platelets — coordinate with stroke/neuro

— Aspirin, clopidogrel, ticagrelor, prasugrel: platelet transfusion of limited benefit (PATCH trial showed worse outcomes in spontaneous ICH); DDAVP 0.3 mcg/kg for uremic or aspirin-related bleeding has modest evidence

— TXA helpful for mucosal bleeding

— Do NOT routinely transfuse platelets in non-surgical antiplatelet-associated ICH unless procedure planned

— Vitamin K deficiency (malnutrition, abx, malabsorption) — responds to vitamin K

— Liver disease — INR elevation without true anticoagulation; reversal is risky (rebalance)

— DIC — consumptive; treat underlying cause + product replacement

— Acquired factor inhibitors (rare; acquired hemophilia) — distinguish with mixing study

Key distinction: An INR of 3.5 in a cirrhotic is NOT equivalent to an INR of 3.5 in a warfarin patient. Cirrhotics have rebalanced hemostasis (low procoagulants AND low anticoagulants). Reversing with PCC can precipitate portal vein thrombosis. Consult hematology and use targeted product replacement (cryoprecipitate, platelets) rather than reflexive PCC.

Other anticoagulant-related bleeding:

Antiplatelet-related bleeding:

Differential within "elevated INR":

Key Differentials — Non-Coagulopathic Bleeding Mimics

— Structural lesions: aneurysm (intracranial, aortic), AVM, malignancy (GI, GU), diverticulosis, peptic ulcer disease

— Trauma with normal AC status — manage per trauma protocols; reversal not needed if no AC

— Vasculitis, scurvy, connective tissue disease — atypical bleeding patterns

— Hemophilia or von Willebrand disease — factor replacement, DDAVP for vWD type 1

— Acquired hemophilia A: elevated aPTT, normal PT, factor VIII inhibitor — treat with bypassing agents (rFVIIa, FEIBA) and immunosuppression

— ITP, TTP, HIT, drug-induced (heparin, vancomycin, linezolid, valproate)

— Treat underlying cause; HIT specifically requires stopping heparin and starting non-heparin AC (argatroban, bivalirudin, fondaparinux) — do NOT give platelets in HIT (paradoxical thrombosis)

— Sepsis, malignancy, trauma, obstetric emergencies

— Schistocytes on smear, low fibrinogen, elevated D-dimer, thrombocytopenia, elevated PT/aPTT

— Treat underlying cause; replace products as needed

— Munchausen, intentional overdose of warfarin (suicide attempt or assault) — psych consult, social work

— Brodifacoum (long-acting "superwarfarin" rodenticide) ingestion — INR remains elevated for weeks to months; requires prolonged high-dose oral vitamin K (50–100 mg/day), sometimes for 6+ months; reversal of acute bleed same as warfarin

— Salicylate poisoning, snake envenomation, herbal supplements (ginkgo, garlic)

Board pearl: A patient with persistently elevated INR despite vitamin K and PCC, denies warfarin use, has access to rodenticides — think brodifacoum ingestion. Quantitative serum brodifacoum level confirms; treat with prolonged vitamin K1 (phytonadione) and engage psychiatry/social work for intentional ingestion vs. occupational exposure.

Bleeding without anticoagulation effect — consider:

Thrombocytopenia-driven bleeding:

Disseminated intravascular coagulation (DIC):

Pseudo-bleeding presentations:

Drug-induced coagulopathy without prescribed AC:

Secondary Prevention, AC Resumption, and Discharge Medications

— ICH: generally restart 4–8 weeks post-bleed for AFib (longer if lobar bleed → higher rebleed risk); 2 weeks for high-risk indications (mechanical valve, recent VTE). RESTART trial supports resumption.

— GI bleed: restart 7–14 days post-hemostasis after successful endoscopic treatment + PPI; earlier in high thrombotic risk

— Major non-CNS bleed: restart once hemostasis achieved and underlying source controlled

— Mechanical valve bleeding: bridge with UFH within 24–72 hours of hemostasis, transition to warfarin

— Post-GI bleed on warfarin or rivaroxaban/dabigatran → consider switch to apixaban (lowest GI bleed rate among DOACs)

— Post-ICH → consider apixaban; alternatively LAA occlusion (Watchman) for AFib patients unable to tolerate AC

— Mechanical valve → no DOAC option; warfarin only

— Discontinue concurrent antiplatelets if dual therapy was given for AFib + CAD beyond required duration (typically 1 year post-PCI, less in stable CAD)

— PPI for GI bleed history or high GI bleed risk on AC

— Reduce alcohol, NSAID counseling

— Treat H. pylori if present

— Fall prevention: PT/OT referral, home safety evaluation, vision check, medication review for falls risk

— Resumed AC with clear date, dose, and follow-up plan

— PPI when indicated

— Antihypertensives if SBP elevated (especially post-ICH; tight BP control reduces rebleed)

— Statin if indicated; address comorbidities

— Reconciliation: discontinue duplicates, document interactions

Step 3 management: For a 70-yo with AFib (CHA₂DS₂-VASc 4) and post-PCC reversed warfarin ICH, switch to apixaban 5 mg BID restarted at 4–8 weeks with neurology and cardiology input, start amlodipine for SBP <130 goal, add PPI, refer to fall prevention clinic, and discuss Watchman LAA occlusion if rebleed risk remains high.

When to resume anticoagulation after bleeding:

Agent selection after bleed:

Risk modification:

Discharge medication checklist:

Follow-Up, Monitoring, and Patient Counseling

— Confirm hemostasis sustained ≥24–48 hours

— Stable Hgb on serial CBCs, normalized vital signs

— Bowel function normal post-GI bleed; tolerating diet

— Disposition decision: home with services, SNF, rehab — based on functional status post-bleed

— Primary care within 7 days of discharge for medication reconciliation, BP check

— Specialty follow-up within 2–4 weeks: cardiology (AFib, valve), hematology (complex restart), neurology (post-ICH)

— Repeat imaging: post-ICH brain MRI/CT at 4–6 weeks to assess resolution and lobar vs. deep location (informs restart decision)

— Endoscopy repeat at 6–8 weeks for high-risk ulcers or unclear etiology

— Warfarin: INR weekly until stable, then every 4 weeks; goal 2–3 (mechanical mitral valve 2.5–3.5)

— DOACs: annual CBC, BMP, LFTs; more frequent if CKD or hepatic disease; no routine drug-level monitoring

— Renal function reassessment every 6–12 months; sooner if acute illness, new medication

— Drug name, dose, time of day (consistency matters for warfarin and BID DOACs)

— Missed dose protocol specific to each drug

— Bleeding warning signs: bright red or coffee-ground emesis, melena, hematuria, severe headache, sudden weakness, easy bruising

— Avoid NSAIDs, certain herbs (ginkgo, St. John's wort), excessive alcohol

— Carry medical alert ID and updated medication list

— Pre-procedure protocols: when to hold AC, when to resume, bridging needs (rare for DOACs)

— Updated medication list to outpatient providers, including reversal agent given (relevant if rebleed within weeks)

— Document indication for AC and target duration clearly

Board pearl: A patient who misses an apixaban dose should take it as soon as remembered on the same day; skip if it's the next day (do NOT double up). Warfarin: take missed dose same day; if remembered next day, skip — and never double up. This counseling appears on Step 3 communication questions.

Hospital discharge planning:

Follow-up cadence:

Monitoring parameters by drug:

Patient counseling — discharge teach-back:

Care transitions:

Ethical, Legal, and Patient Safety Considerations

— Life-threatening bleed in altered patient: implied consent for reversal — proceed and document

— Surrogate decision-maker hierarchy if patient lacks capacity: spouse, adult child, parent, sibling (state-specific)

— Jehovah's Witness with major bleed: PCC and recombinant factor concentrates are typically acceptable (non-blood-product origin) — FFP, pRBC, platelets are not. Document explicit preferences; engage hospital ethics if conflict

— Advance directives must be reviewed before initiating aggressive care; honor DNR/DNI unless reversed by patient or surrogate

— Wrong reversal agent (idarucizumab for Xa inhibitor, or vice versa) — a sentinel event

— Forgotten vitamin K with PCC → recurrent coagulopathy after PCC clears

— Failure to reconcile last AC dose timing — leads to unnecessary or insufficient reversal

— DOAC dose not adjusted for renal function — accumulates and causes spontaneous bleeding

— Use barcoded medication administration; double-check reversal agent identity and dose

— ED-to-floor and floor-to-discharge handoffs are highest-risk for AC errors

— Use structured handoff (SBAR/I-PASS) documenting AC status, last dose, reversal given, restart plan

— Medication reconciliation at every transition; verify with pharmacy

— Suspected elder abuse (unusual bruising patterns, neglect of medication management) — adult protective services

— Suspected intentional overdose/suicide attempt — psychiatric evaluation, safety plan, follow-up

— Firearm safety counseling if patient at risk and on AC

— Andexanet costs ~$25,000+; access is limited — most institutions use 4F-PCC pragmatically

— Document the rationale for agent selection

— Address adherence barriers: cost, transportation, health literacy

Step 3 management: When a patient on warfarin presents with major bleeding and refuses blood products on religious grounds, document the conversation, offer non-blood-product alternatives (4F-PCC, recombinant factors, cell salvage, TXA), engage chaplain and ethics, and respect autonomy even if outcome is unfavorable. The Step 3 answer prioritizes shared decision-making and respect for patient values.

Informed consent in emergencies:

High-risk medication errors (patient safety):

Transitions of care:

Mandatory reporting:

Health systems and disparities:

High-Yield Associations and Rapid-Fire Facts

— Warfarin → 4F-PCC + vitamin K (FFP if PCC unavailable)

— Dabigatran → idarucizumab (or hemodialysis)

— Apixaban/rivaroxaban → andexanet alfa (or 4F-PCC 50 U/kg)

— Edoxaban → 4F-PCC (andexanet off-label)

— Heparin → protamine

— LMWH → protamine (partial)

— Fondaparinux → andexanet (off-label) or rFVIIa

— tPA → cryoprecipitate, FFP, TXA, platelets

— Normal TT excludes dabigatran effect

— PT/aPTT can be normal with therapeutic Xa inhibitor — don't be fooled

— Anti-Xa level: drug-calibrated, quantitative

— INR target for warfarin reversal in major bleed: <1.5 (<1.3 for ICH per some guidelines)

— DOACs cleared in ~3–5 half-lives if normal renal function (~24–48h for most)

— Reversal generally unnecessary if last dose >24h ago with normal renal function and clinical stability — but treat empirically if major bleed

— Mechanical mitral valve + bleed = highest thrombotic stakes

— Apixaban = lowest GI bleed and ICH rate among DOACs

— Dabigatran = highest GI bleed rate; only DOAC that is dialyzable

— Rivaroxaban = once daily, taken with food (15/20 mg dose) for absorption

— Warfarin INR ↑ with: amiodarone, TMP-SMX, metronidazole, fluconazole, fluoroquinolones, macrolides

— DOAC levels ↑ with: ketoconazole, ritonavir, clarithromycin (CYP3A4/P-gp inhibitors)

— DOAC levels ↓ with: rifampin, phenytoin, carbamazepine

— ANNEXA-4: andexanet for Xa inhibitor bleed

— RE-VERSE AD: idarucizumab for dabigatran

— INCH: PCC vs FFP in warfarin ICH (PCC superior)

Board pearl: "Patient on apixaban with ICH and last dose 6 hours ago" → andexanet high-dose if available, 4F-PCC 50 U/kg otherwise. Distractor: idarucizumab (wrong drug).

Drug ↔ reversal agent pairing (memorize cold):

Lab pearls:

Time-since-last-dose pearls:

Highest-risk scenarios:

Drug interaction quick hits:

Trial recall:

Board Question Stem Patterns

— Stem describes AFib patient on "a novel oral anticoagulant taken twice daily" with ICH; lab shows prolonged aPTT and TT → dabigatran → idarucizumab

— Or: "once daily, dose-reduced for CrCl 25" → rivaroxaban or edoxaban

— INR 8 with no bleeding on warfarin → hold warfarin + oral vitamin K 2.5–5 mg; do NOT give PCC

— INR 4.5 with no bleeding → hold 1–2 doses, reduce maintenance, recheck; vitamin K not routinely needed

— Mechanical mitral valve patient with GI bleed on warfarin → PCC + vitamin K, hold warfarin, restart UFH within 24–72h after hemostasis, transition back to warfarin (NOT DOAC)

— Patient started on amiodarone or TMP-SMX while on warfarin develops bleeding with INR 8 → recognize interaction, adjust dose, manage bleed per severity

— Choose PCC, TXA, cell salvage, recombinant factors over FFP/pRBC; document informed refusal

— Lobar ICH (CAA) → generally do NOT resume oral AC; consider LAA occlusion for AFib

— Deep ICH from hypertensive cause → restart at 4–8 weeks with BP control

— Always ask about CrCl and last dose timing in your reasoning

— Activated charcoal if ingestion within 2–4 hours

— Switch from warfarin to LMWH or UFH per trimester; reverse warfarin pre-delivery

— De-escalate triple therapy; usually drop aspirin (AUGUSTUS trial) and continue P2Y12 + apixaban

Step 3 management: The most common Step 3 trap is giving FFP first for warfarin ICH — the correct answer is 4F-PCC + IV vitamin K because PCC is faster, more concentrated, and superior in trial data (INCH trial). FFP is acceptable only when PCC is unavailable.

Pattern 1 — Identify the agent and reverse:

Pattern 2 — INR elevation without bleeding:

Pattern 3 — Mechanical valve + bleed:

Pattern 4 — Drug interaction–induced bleed:

Pattern 5 — Jehovah's Witness bleed:

Pattern 6 — Post-ICH AC restart:

Pattern 7 — DOAC overdose without renal function info:

Pattern 8 — Pregnant mechanical valve patient:

Pattern 9 — Post-PCI patient with AFib bleeding:

One-Line Recap

For any anticoagulant-related major bleed, identify the drug, the time since last dose, the renal function, and the severity — then deploy the specific reversal agent (4F-PCC + vitamin K for warfarin, idarucizumab for dabigatran, andexanet or 4F-PCC for Xa inhibitors), achieve mechanical source control, and plan thoughtful, indication-driven re-initiation of anticoagulation once hemostasis is durable.

— Warfarin ICH or major bleed → 4F-PCC (25–50 U/kg based on INR) + vitamin K 10 mg IV; target INR <1.5 within 60 minutes

— Dabigatran major bleed → idarucizumab 5 g IV (two 2.5 g vials); hemodialysis if antidote unavailable; activated charcoal if recent ingestion

— Apixaban/rivaroxaban major bleed → andexanet alfa (high-dose if last dose <8h and ≥10 mg apixaban or ≥10 mg rivaroxaban) OR 4F-PCC 50 U/kg; PT/aPTT may be normal — don't be falsely reassured

— Restart strategy → mechanical valve 24–72h post-hemostasis (UFH bridge to warfarin); AFib post-GI bleed 7–14d; AFib post-ICH 4–8 weeks; consider apixaban switch (lowest bleed rate) or Watchman LAA occlusion if AC truly untenable

— Reversal alone never substitutes for mechanical source control (endoscopy, surgery, embolization, neurosurgery)

— Thrombosis after reversal is an expected risk, not a treatment failure — mitigate by timely AC resumption

— Every AC patient needs a documented indication, target INR or dose, renal function, and restart plan at every care transition

Board pearl: If you remember nothing else: warfarin → PCC + K; dabigatran → idarucizumab; Xa inhibitors → andexanet or PCC; heparin → protamine; tPA → cryo + TXA. This single mnemonic answers ~80% of Step 3 reversal questions.

Top 4 high-yield recap bullets:

The three universal truths: